Introduction
============

The phenomenon of high rates of aerobic glycolysis in cancer cells was described as early as in the late 1920s by Otto Warburg. Subsequently, metabolic reprogramming has been found to be one of the core hallmarks of cancer, which might enable cancer cells to survive a hostile microenvironment and sustain rapid growth [@B1]. The high rate of glucose utilization by such tumors can be visualized clinically by ^18^fluorine-labeled-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT). In differentiated thyroid cancer, FDG uptake has important prognostic implications. Positive FDG-PET/CT scan was associated with a short thyroglobulin doubling time, and patients with FDG-avid lesions might have shorter survival [@B2], [@B3]. These observations suggest that a glycolytic state links to aggressive tumor biology of thyroid cancer.

Age is a major determining factor for overall survival in patients with thyroid cancer. We have shown that older age at diagnosis is associated with an upregulation of glycolysis signature in tumor tissue [@B4]. It is well recognized that mitochondrial alterations are involved in a diverse range of acquired disorders, including aging and neurodegenerative diseases [@B5]. There is compelling evidence that bioenergetic changes in mitochondria are actively participating in the metabolic reprogramming during tumorigenesis [@B6]. Among metabolic regulators, peroxisome proliferator-activated receptor γ coactivator 1α (PGC1α) is a transcription factor coactivator which plays a pivotal role in mitochondrial biogenesis and function [@B7]. Cellular PGC1α is regulated by stress sensors such as AMP-activated protein kinase (AMPK). Experimental studies suggest that PGC1α is also important in the metabolic reprogramming of cancer cells and is aberrantly regulated by several oncogenes and signaling pathways [@B8].

Recently, we employed next-generation sequencing technology to profile the changes in gene expression during tumor progression. The functional enrichment analysis indicated that the oxidation-reduction pathway was downregulated, and the PGC1α expression was significantly decreased from stage I to stage IV in papillary thyroid cancer [@B9]. Because of the crucial importance of interactions between PGC1α and metabolic reprogramming, we sought to investigate the clinicopathological significance of PGC1α expression in thyroid cancer. Furthermore, we aimed to assess whether manipulation of PGC1α expression would affect the phenotype of thyroid cancer and whether targeting PGC1α could be utilized as a therapeutic strategy in the management of thyroid cancer.

Materials and Methods
=====================

Patient cohort
--------------

The study (14MMHIS091e) was approved by the Institutional Review Board of MacKay Memorial Hospital. Consecutive patients who underwent thyroidectomy for thyroid cancer between 2001 and 2012 were randomly selected for tissue analysis. The details of the selection process have been described in our previous study, and the scanned pathologic images were publicly available for automatic quantitative evaluation [@B10], [@B11]. The criteria of specific pathologic features were described elsewhere [@B12], [@B13]. In the present study, a total of 121 patients with papillary thyroid cancer were included for the PGC1α expression analysis in tumor samples and adjacent normal thyroid tissues. The tumor-node-metastasis (TNM) staging was based on the seventh edition of the American Joint Committee on Cancer staging classification.

Immunohistochemistry
--------------------

The expression level of PGC1α was investigated in paraffin sections using immunohistochemistry with a polyclonal antibody to PGC1α (ab54481; Abcam, Cambridge, UK). Immunohistochemical staining was performed using standard techniques as previously described [@B14]. We observed that the expression of PGC1α in thyroid follicular cells exhibited characteristic nuclear staining and homogeneous cytoplasmic staining (Figure [1](#F1){ref-type="fig"}A). Accordingly, the presence of any areas with ≥50% follicular cells showing definitive nuclear staining were considered PGC1α-positive.

The Cancer Genome Atlas (TCGA) data analysis
--------------------------------------------

The transcriptome sequencing data of primary tumor samples of TCGA papillary thyroid cancer (THCA) dataset were downloaded from the Genomic Data Commons of the National Cancer Institute as previously reported [@B15]. The PGC1α expression level was measured as log-transformed RNA-Seq by Expectation-Maximization (RSEM) values.

Cell culture and reagents
-------------------------

Follicular cell-derived thyroid cancer cell lines K1, FTC-133, and 8505C were obtained from the European Collection of Authenticated Cell Cultures (ECACC), Salisbury, UK, and ML-1 from the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ), Braunschweig, Germany. PGC1α-expressing lentivirus vector, control lentivirus vector, PGC1α-targeting siRNA, and control scramble siRNA were purchased from Santa Cruz Biotechnology, Dallas, TX. AICAR, a cell-permeable AMPK activator, and LY294002, a selective phosphatidylinositol 3-kinase (PI3K) inhibitor, were obtained from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany). PLX4032 (vemurafenib), a BRAF inhibitor, was obtained from Selleck Chemicals, Houston, TX.

Cell growth and clonogenic assay
--------------------------------

Cell viability and growth were determined by trypan blue exclusion. Cells were harvested, stained with 0.4% trypan blue solution (Sigma-Aldrich), and counted in hemocytometer chambers. For the colony-forming assay, 500 thyroid cancer cells were seeded into six-well plates. After 10-14 days, colonies were stained with 3% crystal violet and counted [@B16].

Real-time quantitative polymerase chain reaction
------------------------------------------------

Real-time quantitative polymerase chain reaction (qRT-PCR) was performed to determine the relative mRNA expression of specific genes as previously described [@B17]. The list of primer sequences is provided in Supplementary Table [S1](#SM0){ref-type="supplementary-material"}.

Western blot analysis
---------------------

Nuclear and cytoplasmic protein extracts were prepared using the CelLytic NuCLEAR Extraction Kit (Sigma-Aldrich). Immunoblotting was performed with antibodies against PGC1α (ab54481; Abcam), lamin B1 (ab16048; Abcam), phospho-AMPKα (ab133448; Abcam), AMPKα (ab80039; Abcam), phospho-AKT (\#4056; Cell Signaling Technology, Danvers, MA), AKT (\#4685; Cell Signaling), phospho-ERK (\#4376; Cell Signaling), ERK (\#4695; Cell Signaling), or β-actin (A5441; Sigma-Aldrich) as indicated [@B18].

Metabolic analyses
------------------

Oxygen consumption rate (OCR) was determined using the XF24 Extracellular Flux Analyzer (Seahorse Bioscience; Agilent Technologies, North Billerica, MA) [@B19]. Glucose consumption, ATP content, and lactate production were evaluated using the Glucose Uptake Assay Kit, ATP Assay Kit, and Lactate Assay Kit (all from Sigma-Aldrich), respectively, according to the manufacturer\'s recommendations. To visualize mitochondria, cells were stained with MitoTracker Red CMXRos (Thermo Fisher Scientific) for 30 min. Nuclear counterstaining was performed using 4\',6-diamidino-2-phenylindole (DAPI). Fluorescent images were acquired with a fluorescence microscope.

Xenograft model of thyroid cancer
---------------------------------

All animal care and experiments were approved by the Institutional Animal Care and Use Committee of MacKay Memorial Hospital. Establishment of the murine xenograft tumor model was performed as previously described [@B20]. Six-week-old female BALB/c nude mice purchased from the National Laboratory Animal Center, Taipei, Taiwan, received subcutaneous injections of 1 x 10^7^ thyroid cancer cells into their bilateral flanks. Tumor volume was measured twice weekly.

Statistical analysis
--------------------

Patient data were analyzed using the chi-square test, Fisher\'s exact test, the Cochran-Armitage trend test, or the Mann-Whitney *U* test, as appropriate. Statistical comparisons of independent experiments were performed using two-tailed Student\'s *t* tests. A *P* value \< 0.05 was considered statistically significant.

Results
=======

PGC1α is downregulation in thyroid cancer
-----------------------------------------

We started with the immunohistochemical analysis of PGC1α expression in papillary thyroid cancer. As shown in Figure [1](#F1){ref-type="fig"}A, normal thyroid tissues exhibited strong nuclear immunoreactivity for PGC1α with little staining in the intervening stroma. The expression of PGC1α was diminished in some of the papillary thyroid cancers. Western blotting was performed using proteins isolated from additional paired samples, and the results were in agreement with the immunohistochemical data (Figure [1](#F1){ref-type="fig"}B). PGC1α expression was consistently low in malignant thyroid tissue except that a slight increase in PGC1α expression was observed in some follicular thyroid cancers. Phosphorylated AMPK and phosphorylated AKT levels were overexpressed in the malignant counterparts.

The translational relevance of PGC1α downregulation in thyroid cancer was investigated by examining the clinicopathological correlation. Based on our predefined criteria, about 56% of papillary cancer was interpreted as negative for PGC1α expression. We found that patients with PGC1α-negative papillary cancer had large tumor size, more frequent extrathyroidal or lymphovascular invasion, higher incidence of lymph node metastasis, and more advanced TNM stage (Table [1](#T1){ref-type="table"}). Of note, the majority of PGC1α-negative cancer harbored the BRAF V600E mutation.

For external validation, TCGA data were evaluated for the association between PGC1α expression and clinicopathological factors. The level of PGC1α expression in papillary thyroid cancer was lower than that in the matched normal sample (n = 59; median RSEM, 269 versus 1828; Wilcoxon signed-rank *P* \< 0.0001). PGC1α expression was progressively downregulated along with the increasing disease stage or the increasing recurrence risk defined by the American Thyroid Association (Figure [2](#F2){ref-type="fig"}). The expression of PGC1α tends to further downregulated in the distant metastatic sites than the primary tumor (n = 8; median RSEM, 142 versus 303; *P* = 0.069). Moreover, tumors harboring the *TERT* promoter mutation tend to have lower PGC1α expression (*P* = 0.069), but the marginal difference was lost after propensity score matching for the TNM stage and other clinicopathological parameters (*P* = 0.54) [@B21]. Overall, the analysis of TCGA data confirmed our observation that PGC1α expression was downregulated in parallel to disease progression of papillary thyroid cancer.

PGC1α correlates with oxidative metabolism and is upregulated by AKT inhibition
-------------------------------------------------------------------------------

We investigated cellular respiration and metabolism by Seahorse assay and correlated the measured OCR with PGC1α expression in a panel of thyroid cancer cell lines. As shown in Figure [3](#F3){ref-type="fig"}A, the oxygen consumption of thyroid cancer cells was modestly related to the PGC1α expression level (R^2^ = 0.52, *P* \< 0.0001).

Following treatment with AICAR, phosphorylated AMPK was increased in FTC-133 and K1 cells, but there was no significant change in PGC1α expression (Figure [3](#F3){ref-type="fig"}B). Treatment with LY294002 suppressed AKT activity but upregulated AMPK and ERK phosphorylation. Interestingly, a remarkable increase in PGC1α expression was observed following LY294002 administration. Treatment with PLX4032 upregulated PGC1α expression in FTC-133 but not K1 cells. Taken together, PGC1α downregulation in malignant thyroid tissue probably results from the activation of the AKT pathway.

PGC1α overexpression augments oxidative metabolism
--------------------------------------------------

To gain an insight into the therapeutic potential of the restoration of PGC1α expression, K1 and 8505C cells which had low PGC1α expression levels were transfected with a PGC1α-expressing lentivirus vector. As expected, the expression of mitochondrial gene targets of PGC1α involved in oxidative phosphorylation (COX4i and cytochrome c) were upregulated (Figure [4](#F4){ref-type="fig"}A). Most glycolysis regulators, including glucose transporter (GLUT1), hexokinase 2 (HK2), and pyruvate kinase muscle isozyme 2 (PKM2), were downregulated. Nonetheless, the expression of lactate dehydrogenase (LDHA) was increased along with PGC1α overexpression. Consistent with the role of PGC1α in association with mitochondrial biogenesis, PGC1α-overexpressing thyroid cancer cells showed an increase in MitoTracker red fluorescence, an indicator of mitochondrial mass (Figure [5](#F5){ref-type="fig"}).

In accordance with the changes in mRNA expression of corresponding genes, PGC1α-overexpressing thyroid cancer cells had an increase in the OCR and ATP levels (Figure [4](#F4){ref-type="fig"}C and [4](#F4){ref-type="fig"}E). PGC1α-overexpressing K1 cells had lower glucose consumption (Figure [4](#F4){ref-type="fig"}D). Furthermore, lactate production was increased following PGC1α overexpression (Figure [4](#F4){ref-type="fig"}F), consistent with an upregulation of LDHA. Taken together, the restoration of PGC1α expression led to a relatively augmented oxidative metabolism and glycolysis in thyroid cancer cells.

Accompanied by alterations in metabolic phenotype after PGC1α overexpression, the cell growth and clonogenic ability of K1 cells were significantly increased (Figure [4](#F4){ref-type="fig"}B and [4](#F4){ref-type="fig"}G). There was no change in growth or colony formation in 8505C cells transfected with a PGC1α-expressing lentivirus vector. Our xenograft tumor model supports the *in vitro* results. Subcutaneous transplantation of PGC1α-overexpressing K1 cells in nude mice formed a significantly higher tumor burden compared to control cells (Figure [4](#F4){ref-type="fig"}H).

PGC1α silencing induces a glycolytic phenotype
----------------------------------------------

We further examined the effects of PGC1α knockdown in thyroid cancer cells with relatively high PGC1α expression levels. FTC-133 and ML-1 cells were transfected with PGC1α-targeting siRNA, and the expression of COX4i and cytochrome c was consistently reduced (Figure [6](#F6){ref-type="fig"}A). MitoTracker fluorescent staining supports a decrease in mitochondrial activity (Figure [7](#F7){ref-type="fig"}). Interestingly, the expression of all glycolytic genes (GLUT1, HK2, PKM2, and LDHA) was significantly upregulated. Markedly, the OCR and ATP levels were decreased following PGC1α knockdown (Figure [6](#F6){ref-type="fig"}C and [6](#F6){ref-type="fig"}E). By contrast, glucose consumption and lactate production were increased (Figure [6](#F6){ref-type="fig"}D and [6](#F6){ref-type="fig"}F), consistent with a shift to the glycolytic phenotype.

The change in metabolic phenotype after PGC1α knockdown did not enhance the aggressiveness of thyroid cancer cells. On the contrary, the cell growth and clonogenic ability of FTC-133 and ML-1 cells reduced (Figure [6](#F6){ref-type="fig"}B and [6](#F6){ref-type="fig"}G). In addition, the xenograft tumor growth in nude mice of FTC-133 cells transfected with PGC1α-targeting siRNA was significantly slower (Figure [6](#F6){ref-type="fig"}H). Taken together, although PGC1α silencing induced a glycolytic phenotype in thyroid cancer cells, it did not promote cell proliferation or tumor growth.

Discussion
==========

Energy supply in normal thyrocytes mostly relies on mitochondrial oxidative phosphorylation. In thyroid malignancies, oncogene activation and/or tumor suppressor inactivation leads to a variety of metabolic modifications including an accelerated glycolytic activity [@B22]. The metabolic ecology may, in turn, support tumor progression [@B1]. In this regard, BRAF V600E, the most prevalent somatic oncogenic mutation in papillary thyroid cancer, confers a higher likelihood of FDG-PET avidity and is associated with higher standardized uptake values (SUVs) [@B23]. This is in line with the findings of the present study. We showed that the PGC1α expression was downregulated in advanced disease and was closely related to the occurrence of BRAF V600E mutation. The downregulation of PGC1α in thyroid cancer likely reflects compromised mitochondrial integrity, reduced respiration, and compensatory enhancement in glycolysis during tumor progression. It is consistent with the observed relationship between the FDG-PET avidity and patient outcomes [@B3].

PGC1α acts as a key conduit for AMPK to control the expression of metabolic genes [@B24]. In agreement with our observations, Vidal and colleagues demonstrated that phosphorylated AMPK was upregulated in papillary thyroid cancer [@B25]. However, the relationship of phosphorylated AMPK and nuclear PGC1α expression was in the opposite direction. Furthermore, AICAR treatment in thyroid cancer cells increased AMPK phosphorylation but not PGC1α expression. Therefore, it is unlikely that AMPK is the main regulator of PGC1α expression in thyroid cancer. Previous studies indicated that phosphorylation of PGC1α by AKT could attenuate PGC1α activity [@B7], [@B26]. Aberrant activation of the PI3K/AKT pathway is involved in the progression and dedifferentiation of thyroid cancer [@B27], [@B28]. It is also worth noting that FDG uptake in tumors may correlate with AKT pathway activity [@B29], [@B30]. Taken together, our results suggest that PGC1α expression and metabolic phenotype were largely regulated by the PI3K/AKT pathway rather than the AMPK pathway in thyroid cancer.

Considering the clinical implications of the glycolytic shift in thyroid cancer, it would be interesting to evaluate the therapeutic potential of manipulating PGC1α expression levels with accompanying changes in metabolic phenotypes. As expected, cells transfected with a PGC1α-expressing vector had increased oxidative metabolism and aerobic glycolysis through the induction of metabolic genes. Strikingly, cell growth and tumor formation of the PGC1α-overexpressing cells in immunocompromised mice were also enhanced. On the other hand, although glycolysis was upregulated following siRNA-mediated silencing of PGC1α, mice injected with PGC1α-knockdown FTC-133 cells showed a significant delay in tumor growth. A reasonable interpretation of our findings is that the metabolic characteristics might be cell-context dependent intrinsic properties acquired during disease progression. In this sense, simply modifying the balance between glycolysis and oxidative metabolism would not translate into beneficial effects.

In conclusion, the expression of PGC1α in thyroid cancer samples is negatively regulated by AKT activity, and the PGC1α expression is reduced at a later stage of the disease or in BRAF-mutant tumors. We observed a positive correlation between the PGC1α expression and oxygen consumption in thyroid cancer cells. PGC1α overexpression augmented oxidative metabolism as well as glycolysis and promoted colony formation and xenograft tumor growth. Silencing PGC1α induced a glycolytic phenotype and delayed the tumor growth. These findings suggest the metabolic phenotype is likely the consequence rather than the cause of disease progression in thyroid cancer.

Supplementary Material {#SM0}
======================

###### 

Supplementary table.

###### 

Click here for additional data file.

This research was supported by research grants from the Ministry of Science and Technology of Taiwan (MOST-104-2314-B-195-004-MY3 and MOST-107-2314-B-195-001-MY3) and MacKay Memorial Hospital (MMH-10712, MMH-E-108-10, and MMH-10813).

![Expression of peroxisome proliferator-activated receptor γ coactivator 1α (PGC1α) in normal thyroid tissue and papillary thyroid cancer (negative/weak, moderate, or strong expression). **(A)** Representative microscopic photographs of immunohistochemical staining. Original magnification, 400x. **(B)** Western blot analysis of nuclear and cytoplasmic protein extracts from paired samples (N, normal; T, tumor). Lamin and actin were used as nuclear and cytoplasmic loading controls, respectively. \*, papillary thyroid cancer; \#, follicular thyroid cancer.](jcav10p3819g001){#F1}

![Expression of peroxisome proliferator-activated receptor γ coactivator 1α (PPARGC1A) in papillary thyroid cancer (THCA) dataset of The Cancer Genome Atlas (TCGA). \*\*\*, *P* \< 0.001.](jcav10p3819g002){#F2}

![**(A)** The correlation of oxygen consumption rate (OCR) and peroxisome proliferator-activated receptor γ coactivator 1α (PGC1α) expression in thyroid cancer cell lines. **(B)** Western blot analysis of nuclear and cytoplasmic protein extracts from FTC-133 and K1 cells treated with vehicle control, AICAR 1 mM, LY294002 20 μM, or PLX4032 20 μM for 24 h. Lamin and actin were used as nuclear and cytoplasmic loading controls, respectively.](jcav10p3819g003){#F3}

![Phenotypic characteristics of thyroid cancer cell lines (K1 and 8505C) transfected with a PGC1α-expressing lentivirus vector (Lenti-PGC1α) versus control lentivirus vector (Lenti-Ctrl). **(A)** Relative changes in mRNA expression of metabolic genes. **(B)** Cell growth. **(C)** Oxygen consumption rate (OCR). **(D)** Glucose consumption. **(E)** ATP content. **(F)** Lactate production. **(G)** Colony formation. **(H)** Xenograft tumor growth of K1 thyroid cancer cells in nude mice (n = 4 per group). \*, *P* \< 0.05; \#, *P* \< 0.001.](jcav10p3819g004){#F4}

![MitoTracker staining of K1 and 8505C thyroid cancer cells transfected with a control lentivirus vector (Lenti-Ctrl) or PGC1α-expressing lentivirus vector (Lenti-PGC1α). Nuclear counterstaining was performed using 4\',6-diamidino-2-phenylindole (DAPI). Scale bar, 100 μm.](jcav10p3819g005){#F5}

![Phenotypic characteristics of thyroid cancer cell lines (FTC-133 and ML-1) transfected with a PGC1α-targeting siRNA (siRNA-PGC1α) versus control scramble siRNA (siRNA-Scr). **(A)** Relative changes in mRNA expression of metabolic genes. **(B)** Cell growth. **(C)** Oxygen consumption rate (OCR). **(D)** Glucose consumption. **(E)** ATP content. **(F)** Lactate production. **(G)** Colony formation. **(H)** Xenograft tumor growth of FTC-133 thyroid cancer cells in nude mice (n = 6 per group). \*, *P* \< 0.05; \#, *P* \< 0.001.](jcav10p3819g006){#F6}

![MitoTracker staining of FTC-133 and ML-1 thyroid cancer cells transfected with a control scramble siRNA (siRNA-Scr) or PGC1α-targeting siRNA (siRNA-PGC1α). Nuclear counterstaining was performed using 4\',6-diamidino-2-phenylindole (DAPI). Scale bar, 100 μm.](jcav10p3819g007){#F7}

###### 

Associations between peroxisome proliferator-activated receptor γ coactivator 1α (PGC1α) expression and clinicopathological features in papillary thyroid cancer (n = 121)

                                  PGC1α-negative (n = 68)   PGC1α-positive (n = 53)   *P* value
  ------------------------------- ------------------------- ------------------------- --------------
  Age (years) ^a^                 45 (33-58)                42 (37-49)                0.481
  Sex                                                                                 0.276
  Male                            8 (12%)                   10 (19%)                  
  Female                          60 (88%)                  43 (81%)                  
  Body mass index (kg/m^2^) ^a^   24.0 (21.8-26.5)          23.1 (22.8-24.5)          0.661
  Tumor size (cm) ^a^             2.5 (1.8-3.1)             1.7 (1.2-2.8)             **0.003**
  Extrathyroidal invasion ^b^                                                         **\< 0.001**
  No                              23 (34%)                  41 (77%)                  
  Microscopic                     32 (47%)                  11 (21%)                  
  Macroscopic                     13 (19%)                  1 (2%)                    
  Multifocality                                                                       0.364
  Present                         24 (35%)                  23 (43%)                  
  Absent                          44 (65%)                  30 (57%)                  
  Lymphovascular invasion                                                             **0.012**
  Present                         19 (28%)                  5 (9%)                    
  Absent                          49 (72%)                  48 (91%)                  
  BRAF V600E mutation                                                                 **\< 0.001**
  Present                         61 (90%)                  23 (43%)                  
  Absent                          7 (10%)                   30 (57%)                  
  Lymph node metastasis ^b^                                                           **0.009**
  N0                              27 (40%)                  33 (62%)                  
  N1a                             28 (41%)                  16 (30%)                  
  N1b                             13 (19%)                  4 (8%)                    
  Distant metastasis                                                                  0.255
  Present                         3 (4%)                    0 (0%)                    
  Absent                          65 (96%)                  53 (100%)                 
  TNM stage ^b^                                                                       **0.001**
  Stage I                         36 (53%)                  42 (79%)                  
  Stage II                        2 (3%)                    2 (4%)                    
  Stage III                       17 (25%)                  8 (15%)                   
  Stage IV                        13 (19%)                  1 (2%)                    

Data are expressed as number (percentage) or median (interquartile range). ^a^ Mann-Whitney test, ^b^ Cochran-Armitage trend test.

[^1]: Competing Interests: The authors have declared that no competing interest exists.
